Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 10/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.75 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.74 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.74 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.74 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.74 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.74 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.74 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.74 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.74 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7683504 | 1.00 | PDE5A (0.84) | PDE5AKMT2APAX8HDAC3HDAC4 | |
| SCHEMBL7433397 | 1.00 | PDE5A (0.84) | PDE5AKMT2APAX8HDAC3HDAC4 | |
| SCHEMBL6784109 | 0.93 | PDE5A (0.86) | PDE5AKMT2A | |
| SCHEMBL7714898 | 0.93 | PDE5A (0.86) | PDE5AKMT2A | |
| SCHEMBL7714894 | 0.93 | PDE5A (0.86) | PDE5AKMT2A | |
| SCHEMBL1326142 | 0.92 | PDE5A (0.85) | PDE5A | |
| SCHEMBL1326138 | 0.92 | PDE5A (0.85) | PDE5A | |
| SCHEMBL1326139 | 0.92 | PDE5A (0.85) | PDE5A | |
| SCHEMBL6782147 | 0.91 | PDE5A (0.84) | PDE5A | |
| SCHEMBL6782139 | 0.91 | PDE5A (0.84) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6369059-B1 | INHIBITOR OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE (CGMP SPECIFIC PDE); CARDIOVASCULAR DISORDERS; PYRAZINO(2',1':6,1)PYRIDO(3,4-B)INDOLE-1,4-DIONES | ICOS CORPORATION | 2002-04-09 | — | — | US | disclosed |
| US-20020035111-A1 | Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B] indole derivatives | OSI PHARMACEUTICALS, INC. | 2002-03-21 | — | — | US | disclosed |
| US-6127542-A | CHEMICAL INTERMEDIATES TO SPECIFIED PYRAZINO(2',1':6,1)PYRIDO(3,4B)INDOLE-1,4-DIONES WHICH ARE SELECTIVE INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE; TO TREAT CARDIOVASCULAR DISORDERS | ICOS CORPORATION (US) | 2000-10-03 | — | — | US | disclosed |
| EP-0740668-B1 | TETRACYCLIC DERIVATIVES, PROCESS OF PREPARATION AND USE | ICOS CORP (US) | 1998-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035111-A1 | Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B] indole derivatives | MKI67, PNPO, CDK4 | PDE5A 4371/4885KMT2A 1547/4885PAX8 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.